Xoma | XOMA - Current Liabilities


Xoma reported $28.3M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Agenus USD 249.24M 74.25M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Ardelyx USD 109.57M 20.96M Mar/2026
aTyr Pharma USD 11.7M 101.49M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Celldex Therapeutics USD 51.47M 481K Mar/2026
Curis USD 14.08M 5.3M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Incyte USD 1.49B 25.52M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 34.35B 2.64B Mar/2026
Prothena USD 32.52M 8.33M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Xoma USD 28.3M 6.81M Sep/2025